Navigation Links
CuraGen in Medical News
CuraGen Reports First Quarter 2009 Financial Results
...ANFORD, Conn., April 23 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) , today reported its...uring the three month period ended March 31, 2009, curagen utilized $4.1 million of cash and investments for ...n of cash and investments. As of March 31, 2009, curagen had $14 million of outstanding 4% convertible subo...Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer
...ltant for clients including Genaissance Pharmaceuticals, Amersham Health, G.E. Healthcare and Massachusetts General Hospital. Alsobrook also worked at curagen Corp. as genetics supervisor for drug discovery and as senior research scientist for pharmacogenomics. From 1996-2000, Alsobrook was associate faculty...CuraGen to Present at the Rodman & Renshaw Annual Global Investment Conference
... BRANFORD, Conn., Nov. 5 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...archived for 90 days thereafter. About CuraGen curagen Corporation (Nasdaq: CRGN ) is a dedicated clinic...ng diverse approaches for the treatment of cancer. curagen Corporation is headquartered in Branford, Connecti...... BRANFORD, Conn., June 6 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) announced today that ...archived for 30 days thereafter. About CuraGen curagen Corporation (Nasdaq: CRGN ) is a clinical-stage b... promising approaches for the treatment of cancer. curagen Corporation is headquartered in Branford, Connecti...
CuraGen Corporation Regains NASDAQ Listing Compliance
... BRANFORD, Conn., May 29 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) today announced that ...8, NASDAQ had previously informed the Company that curagen had until July 28, 2008 to regain compliance with ...hank our shareholders who have shown confidence in curagen during this notification period," stated Dr. Timot...CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million
... BRANFORD, Conn., May 22 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) announced today the c...CuraGen's ownership in belinostat. After expenses, curagen will receive approximately $12 million in cash. ...n April 22, 2008, bring the total cash realized by curagen to approximately $38 million," stated Dr. Timothy ...Pharsight Strengthens Senior Management Team
...g strategies and implementing solutions to improve R&D productivity. Before this, Dr. Murphy served as Vice President and Chief Information Officer at curagen Corporation, a publicly traded biopharmaceutical company. While at CuraGen, he directed business development and information technology services for t...CuraGen Reports First Quarter 2008 Financial Results
...RANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) today reported its fi...ter of 2008. For the quarter ended March 31, 2008, curagen reported a net loss of $6.8 million, or $0.12 per ...e same period in 2007. During the first quarter, curagen incurred costs totaling $1.5 million for milestone......BRANFORD, Conn., Dec. 10 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...tology (ASH) 49th Annual Meeting in Atlanta, GA. curagen and TopoTarget also reported today that the prelim...tment of PTCL. Based on this meeting with the FDA, curagen plans to submit a clinical trial protocol to the F...
CuraGen Reports Third Quarter 2007 Financial Results
...BRANFORD, Conn., Oct. 25 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...of 2007. For the quarter ended September 30, 2007, curagen reported a net loss of $9.9 million, or $0.18 per ...he same period in 2006. As of September 30, 2007, curagen had cash and investments of $153.6 million. Of the...CuraGen in Medical Technology
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
...RANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) announced today tha...e Professor of Clinical Medicine, /Weill Cornell. curagen anticipates presenting updated results from this s...n antibody-drug conjugate (ADC) being developed by curagen that consists of a fully-human monoclonal antibody...CuraGen Updates CR011-vcMMAE Data at ASCO
...BRANFORD, Conn., June 2 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) reported three data...n antibody-drug conjugate (ADC) being developed by curagen that consists of a fully-human monoclonal antibody...ancer who have failed other therapies. About curagen CuraGen Corporation (Nasdaq: CRGN ) is a clinica...CuraGen to Present CR011-vcMMAE Data at ASCO
...BRANFORD, Conn., May 28 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) today announced pla...n antibody-drug conjugate (ADC) being developed by curagen that consists of a fully-human monoclonal antibody...n survival is less than nine months. About curagen ...... BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) announced today preli...g schedules of CR011-vcMMAE," commented Dr. Hwu. curagen is currently enrolling patients into a Phase I por...st cancer who have received previous chemotherapy. curagen anticipates providing updated data from the ongoin...
...BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...ays at http://www.curagen.com . About CuraGen curagen Corporation (Nasdaq: CRGN ) is a dedicated clinic...ng diverse approaches for the treatment of cancer. curagen Corporation is headquartered in Branford, Connecti...
CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
...RANFORD, Conn., Sept. 11 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...011-vcMMAE for the treatment of advanced melanoma. curagen also announced today that Phase II results from th...rate, time to response and duration of response. curagen is also continuing the Phase I portion of the tria...CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
...BRANFORD, Conn., July 29 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...011-vcMMAE. For the quarter ended June 30, 2008, curagen reported income from continuing operations of $39....ly negotiated transactions. As of June 30, 2008, curagen had cash, restricted cash and investments of $95.0......BRANFORD, Conn., June 25 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio... Shannon, President and Chief Executive Officer of curagen Corporation. "We are confident in our ability to c...who have failed other therapies. About CuraGen curagen Corporation (Nasdaq: CRGN ) is a dedicated clinic...
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
...BRANFORD, Conn., June 11 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio... Shannon, President and Chief Executive Officer of curagen Corporation. "This trial is enrolling well, and we... cancer in the third quarter of 2008. Furthermore, curagen is conducting preclinical research to determine th...... BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) today presented encou... Shannon, President and Chief Executive Officer of curagen Corporation. "Based on these promising results in ...need in this patient population. About CuraGen curagen Corporation (Nasdaq: CRGN ) is a clinical-stage b...
CuraGen in Biological News
Massey researchers induce cell death in leukemia
...of translational research, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from curagen Corporation and TopoTarget A/S), were examined in human CLL cells isolated from five patients. Bortezomib dramatically potentiated the lethality of bo...CuraGen in Biological Technology
CuraGen Reports Second Quarter 2009 Financial Results
...RANFORD, Conn., July 31 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) today reported its ...are in connection with the proposed merger between curagen Corporation and Celldex Therapeutics, Inc. The se...e three and six month periods ended June 30, 2009, curagen utilized $3.8 million and $7.8 million, respective......BRANFORD, Conn., Jan. 29 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), today reported its f...ng the three month period ended December 31, 2008, curagen utilized $3.8 million of cash and investments and ...on of cash and investments. At December 31, 2008, curagen has outstanding $19 million of 4% convertible subo...
CuraGen Reports Third Quarter 2008 Financial Results
... BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), today reported its f...uarter with $91.4 million of cash and investments. curagen expects to utilize an average of $3 to $4 million ...mately $79 to $81 million in cash and investments. curagen is also pursuing partnership opportunities around ...CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
... BRANFORD, Conn., May 14 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) announced today the c...discount of approximately 15.1% off of face value. curagen currently has approximately $100 million or $1.72 ...ding. With the completion of these transactions, curagen will eliminate a total of approximately $5.6 milli...CuraGen Sells Ownership of Belinostat to TopoTarget A/S
... - curagen to receive approximately $45 million in cash, stoc...RANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio...to future net sales and sublicenses of belinostat. curagen will no longer have any funding requirements for b...TopoTarget Successfully Buys Back Full Control of Belinostat
...duct TopoTarget Acquires US & RoW Rights From curagen Corporation COPENHAGEN, April 22 /PRNewswire/ --...tiple cancer indications jointly by TopoTarget and curagen Corporation since 2004. TopoTarget, which has alre... its flexible dosing, and its lack of toxicity." curagen has accepted to sell their rights back to TopoTarg...CuraGen to Present at the BIO CEO & Investor Conference
...BRANFORD, Conn., Feb. 12 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) announced today that ...'s website until March 13, 2008. About CuraGen curagen Corporation (Nasdaq: CRGN ) is a dedicated clinic...g development strengths cultivated over the years, curagen expects to make a difference by advancing its prom...CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
...BRANFORD, Conn., Jan. 31 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ) today reported its co...quarter and fiscal year ended December 31, 2007. curagen reported a loss from operations for the fourth qua...r of 2006. For the year ended December 31, 2007, curagen reported a loss from operations of $59.6 million, ...CuraGen Corporation Receives Notification from NASDAQ
...BRANFORD, Conn., Jan. 29 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio... 28, 2008, from The NASDAQ Stock Market, notifying curagen that during the preceding 30 consecutive trading d...e effect on the listing of CuraGen's common stock. curagen is considering alternatives to regain compliance w...CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
...BRANFORD, Conn., Dec. 20 /PRNewswire-FirstCall/ -- curagen Corporation (Nasdaq: CRGN ), a clinical-stage bio... Company. "We are pleased to welcome Sean to the curagen team," commented Timothy Shannon, President and Ch...ve Wurzer for his more than 10 years of service to curagen during which he made substantial contributions acr...Other TagsOther Contents
(Date:6/19/2013)... 19, 2013 Kleritec, Inc. announced the ... at http://www.kleritec.com . In the recent expansion ... and activities packages for pre-school and day care providers. ... method to aid teachers across the United States the ... learning. , Included in the art and activities packages ...
(Date:6/19/2013)... June 19, 2013 Today, Zane Benefits, ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... Benefits’ website, as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:6/19/2013)... York, New York (PRWEB) June 19, 2013 ... pancreatitis and pancreatic cancer continue to mount in courts ... U.S. Food & Drug Administration (FDA) recently held a ... diabetes drugs known as incretin mimetics. According to ... seek additional data from the makers of Januvia and ...
(Date:6/19/2013)... and trauma surgery have had a significant impact ... after major injuries, including burns. Patients who ... are at greatest risk from infections particularly ... or from inflammation-induced multiorgan failure. Now, ... investigators that measures the movement of key immune ...
(Date:6/19/2013)... In a study published in the June 19 online ... team led by researchers from the University of California, ... cellular events that take place when cardiac regeneration occurs ... provide evidence that various cell lines in the heart ... cell types, than previously thought. , More importantly, the ...
Breaking Medicine News(10 mins):Health News:Kleritec Announces Addition of Educational Products. 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2[0] Kleritec Announces Addition of Educational Products.[0] Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange[0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics[0] Restoring appropriate movement to immune cells may save seriously burned patients[0] Fate of the heart: Researchers track cellular events leading to cardiac regeneration
(Date:6/18/2013)... a very large "dead zone" in the Gulf of ... the Chesapeake Bay this year, based on several NOAA-supported ... Michigan, Louisiana State University, and the Louisiana Universities ... Mexico hypoxic "dead" zone will be between 7,286 and ... ten largest recorded. That would range from an area ...
(Date:6/18/2013)... June 18, 2013 Joshua Obar, Ph.D., Department ... been honored with a 2013 ICAAC Young Investigator Award ... of immunological memory responses to infection. , Obar ... in 2001 and went on to complete his Ph.D. ... He performed his Ph.D. thesis research in Edward ...
(Date:6/18/2013)... is estimated that between 5% and 10% of breast ... to say that these tumours are attributable to inherited ... or BRCA2. In patients with these mutations, PARP inhibitors, ... results that make them a new option for personalised ... latest studies indicate that a fraction of these patients ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |